Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Sep;60(3):351–357. doi: 10.1038/bjc.1989.284

Enhancement and suppression of DTH reactivity to Rauscher murine leukaemia virus induced tumour cell lines.

A C Knulst 1, D Berends 1, C Bazuin 1, H C van Rooij 1, N J de Both 1, R Benner 1
PMCID: PMC2247201  PMID: 2477052

Abstract

Delayed-type hypersensitivity (DTH) to Rauscher murine leukaemia virus (R-MuLV) encoded or induced determinants was induced in mice by three syngeneic R-MuLV-induced tumour cell lines, i.e. a myeloid tumour, RMB-1, an erythroid tumour, RED-1, and a lymphoid tumour, RLD-1. DTH to subcutaneously (s.c.) administered RMB-1 cells appeared on day 4, with a maximum DTH response on day 6 or 7. The induction of DTH could be prevented by intravenous (i.v.) pre-immunisation with R-MuLV-induced tumour cells several days before the s.c. immunisation. The three R-MuLV-induced tumour cell lines showed cross-reactivity in the DTH assay, whereas no cross-reactivity was found with syngeneic WEHI-3 cells. This indicates that the three R-MuLV-induced tumour cell lines share a virally encoded or induced antigenic determinant, which activates T-cells. When the RMB-1 cells used for immunisation had been cultured in medium supplemented with interferon-gamma (IFN-gamma), the subsequent DTH response was increased. This coincided with an increased expression of the R-MuLV-specific antigenic determinants on RMB-1 cells as demonstrated by Scatchard analysis. Furthermore, IFN-gamma increased the MHC class I antigen expression on RMB-1 cells, whereas the class II antigen expression remained undetectable.

Full text

PDF
351

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bendinelli M., Matteucci D., Friedman H. Retrovirus-induced acquired immunodeficiencies. Adv Cancer Res. 1985;45:125–181. doi: 10.1016/s0065-230x(08)60268-7. [DOI] [PubMed] [Google Scholar]
  2. Berends D., Mulder A. H., van Houwelingen G., de Both N. J. Use of syngeneic monoclonal antibodies in the therapy of disseminated myeloid leukemic cells. Int J Cancer. 1988 Jul 15;42(1):42–47. doi: 10.1002/ijc.2910420109. [DOI] [PubMed] [Google Scholar]
  3. Berends D., Rhijnsburger E. H., van Gaalen J. L., van Houwelingen G., Zondervan P. E., de Both N. J. Syngeneic monoclonal antibodies directed against Rauscher virus-induced myeloid leukemic cells: isolation and characterization. Int J Cancer. 1988 Jul 15;42(1):112–118. doi: 10.1002/ijc.2910420121. [DOI] [PubMed] [Google Scholar]
  4. Berends D., van Gaalen J. L., Rhijnsburger E. H., de Both N. J., Breeman W., Bakker W. H., Kooy P. The detection of virally induced tumors by 131I- and 125I-labeled syngeneic monoclonal antibodies. Cancer Immunol Immunother. 1988;26(3):243–249. doi: 10.1007/BF00199936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Berends D., van der Kwast T. H., de Both N. J., Mulder P. G. Factors influencing antibody-mediated cytotoxicity during the immunotherapy of Rauscher-virus-induced myeloid leukemic cells. Cancer Immunol Immunother. 1989;28(2):123–130. doi: 10.1007/BF00199112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bhattacharya A., Dorf M. E., Springer T. A. A shared alloantigenic determinant on Ia antigens encoded by the I-A and I-E subregions: evidence for I region gene duplication. J Immunol. 1981 Dec;127(6):2488–2495. [PubMed] [Google Scholar]
  7. Bianchi A. T., Hussaarts-Odijk L. M., van der Kwast T. H., Bril H., Benner R. Suppression of antigraft immunity by preimmunization. II. Characterization of the suppressor cells. Transplantation. 1984 May;37(5):490–499. doi: 10.1097/00007890-198405000-00014. [DOI] [PubMed] [Google Scholar]
  8. Bookman M. A., Swerdlow R., Matis L. A. Adoptive chemoimmunotherapy of murine leukemia with helper T lymphocyte clones. J Immunol. 1987 Nov 1;139(9):3166–3170. [PubMed] [Google Scholar]
  9. Crowle A. J. Delayed hypersensitivity in the mouse. Adv Immunol. 1975;20:197–264. doi: 10.1016/s0065-2776(08)60209-6. [DOI] [PubMed] [Google Scholar]
  10. Dijkmans R., Volckaert G., Van Damme J., De Ley M., Billiau A., De Somer P. Molecular cloning of murine interferon gamma (MuIFN-gamma) cDNA and its expression in heterologous mammalian cells. J Interferon Res. 1985 Summer;5(3):511–520. doi: 10.1089/jir.1985.5.511. [DOI] [PubMed] [Google Scholar]
  11. Dye E. S., North R. J., Mills C. D. Mechanisms of anti-tumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations. J Exp Med. 1981 Sep 1;154(3):609–620. doi: 10.1084/jem.154.3.609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Friedman R. M., Maheshwari R. K., Jay F. T., Czarniecki C. Mechanism of interferon inhibition of viruses that bud from the plasma membrane. Ann N Y Acad Sci. 1980;350:533–544. doi: 10.1111/j.1749-6632.1980.tb20655.x. [DOI] [PubMed] [Google Scholar]
  13. Galetto G., Law L. W., Rogers M. J. The Rauscher-MuLV-induced leukemia, RBL-5, bears two tumor-associated transplantation antigens expressed on distinct molecules. Int J Cancer. 1985 Dec 15;36(6):713–719. doi: 10.1002/ijc.2910360616. [DOI] [PubMed] [Google Scholar]
  14. Green W. R., Phillips J. D. Differential induction of H-2K vs H-2D class I major histocompatibility complex antigen expression by murine recombinant interferon-gamma. J Immunol. 1986 Aug 1;137(3):814–818. [PubMed] [Google Scholar]
  15. Greiner J. W., Guadagni F., Noguchi P., Pestka S., Colcher D., Fisher P. B., Schlom J. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science. 1987 Feb 20;235(4791):895–898. doi: 10.1126/science.3580039. [DOI] [PubMed] [Google Scholar]
  16. Halliday W. J., Webb M. Delayed hypersensitivity to chemically induced tumors in mice and correlation with an in vitro test. J Natl Cancer Inst. 1969 Jul;43(1):141–150. [PubMed] [Google Scholar]
  17. Hawrylko E. Induction of delayed-type hypersensitivity and antitumor immunity by systemic BCG. Cell Immunol. 1980 Mar 1;50(1):136–152. doi: 10.1016/0008-8749(80)90013-1. [DOI] [PubMed] [Google Scholar]
  18. Hoover H. C., Jr, Surdyke M., Dangel R. B., Peters L. C., Hanna M. G., Jr Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine. Cancer Res. 1984 Apr;44(4):1671–1676. [PubMed] [Google Scholar]
  19. King D. P., Jones P. P. Induction of Ia and H-2 antigens on a macrophage cell line by immune interferon. J Immunol. 1983 Jul;131(1):315–318. [PubMed] [Google Scholar]
  20. Krim M. Towards tumor therapy with interferons, part II. Interferons: in vivo effects. Blood. 1980 Jun;55(6):875–884. [PubMed] [Google Scholar]
  21. Kripke M. L. Immunologic mechanisms in UV radiation carcinogenesis. Adv Cancer Res. 1981;34:69–106. doi: 10.1016/s0065-230x(08)60239-0. [DOI] [PubMed] [Google Scholar]
  22. Levy J. P., Leclerc J. C. The murine sarcoma virus-induced tumor: exception or general model in tumor immunology? Adv Cancer Res. 1977;24:1–66. doi: 10.1016/s0065-230x(08)61012-x. [DOI] [PubMed] [Google Scholar]
  23. Mizel S. B., DeLarco J. E., Todaro G. J., Farrar W. L., Hilfiker M. L. In vitro production of immunosuppressive factors by murine sarcoma virus-transformed mouse fibroblasts. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2205–2208. doi: 10.1073/pnas.77.4.2205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Morton D. L., Miller G. F., Wood D. A. Demonstration of tumor-specific immunity against antigens unrelated to the mammary tumor virus in spontaneous mammary adenocarcinomas. J Natl Cancer Inst. 1969 Feb;42(2):289–301. [PubMed] [Google Scholar]
  25. North R. J. Down-regulation of the antitumor immune response. Adv Cancer Res. 1985;45:1–43. doi: 10.1016/s0065-230x(08)60265-1. [DOI] [PubMed] [Google Scholar]
  26. Nowinski R. C., Emery S., Ledbetter J. Identification of an FMR cell surface antigen associated with murine leukemia virus-infected cells. J Virol. 1978 Jun;26(3):805–812. doi: 10.1128/jvi.26.3.805-812.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Ozawa H., Iwaguchi T., Kataoka T. The Lyt phenotype of the T cells responsible for in vivo tumor rejection in syngeneic mice. Cancer Immunol Immunother. 1986;23(1):73–77. doi: 10.1007/BF00205559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Paul R. D., Lopez D. M. Induction of "innocent bystander" cytotoxicity in nonimmune mice by adoptive transfer of L3T4+ Lyt-1+2- mammary tumor immune T-cells. Cancer Res. 1987 Feb 15;47(4):1105–1110. [PubMed] [Google Scholar]
  29. Stefanini M., Reuser A., Bootsma D. Isolation of Chinese hamster ovary cells with reduced unscheduled DNA synthesis after UV irradiation. Somatic Cell Genet. 1982 Sep;8(5):635–642. doi: 10.1007/BF01542856. [DOI] [PubMed] [Google Scholar]
  30. Suda T., Fujiwara H., Mizushima Y., Shearer G. M., Hamaoka T. Augmentation of antitumor immune response by trinitrophenyl (TNP)-reactive helper T-cells: enhanced induction of tumor-specific Lyt-1+2- T-cell-mediated delayed-type hypersensitivity from spleen cells of tumor-bearing mice by TNP helpers. J Natl Cancer Inst. 1986 Dec;77(6):1267–1272. [PubMed] [Google Scholar]
  31. Tanaka K., Hayashi H., Hamada C., Khoury G., Jay G. Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc Natl Acad Sci U S A. 1986 Nov;83(22):8723–8727. doi: 10.1073/pnas.83.22.8723. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Warner N. L., Moore M. A., Metcalf D. A transplantable myelomonocytic leukemia in BALB-c mice: cytology, karyotype, and muramidase content. J Natl Cancer Inst. 1969 Oct;43(4):963–982. [PubMed] [Google Scholar]
  33. de Both N. J., Rhijnsburger E. H., van Ewijk W. A Rauscher-virus-induced T-lymphocyte cell line. Induction of differentiation under influence of dimethylsulfoxide and phorbolesters. Int J Cancer. 1983 Oct 15;32(4):501–506. doi: 10.1002/ijc.2910320418. [DOI] [PubMed] [Google Scholar]
  34. de Both N. J., Stoof T. J., Kranendonk M., Stoker K., Vonk W. P., Mol J. N. The induction of myeloid leukaemias by Rauscher murine leukaemia virus. J Gen Virol. 1985 Apr;66(Pt 4):909–913. doi: 10.1099/0022-1317-66-4-909. [DOI] [PubMed] [Google Scholar]
  35. de Both N. J., Vermey M., van't Hull E., Klootwijk-van-Dijke E., van Griensven L. J., Mol J. N., Stoof T. J. A new erythroid cell line induced by Rauscher murine leukaemia virus. Nature. 1978 Apr 13;272(5654):626–628. doi: 10.1038/272626a0. [DOI] [PubMed] [Google Scholar]
  36. van Ewijk W., van Soest P. L., van den Engh G. J. Fluorescence analysis and anatomic distribution of mouse T lymphocyte subsets defined by monoclonal antibodies to the antigens Thy-1, Lyt-1, Lyt-2, and T-200. J Immunol. 1981 Dec;127(6):2594–2604. [PubMed] [Google Scholar]
  37. van der Kwast T. H. H-2-restricted recognition of minor histocompatibility antigens in delayed type hypersensitivity. J Immunogenet. 1980 Aug;7(4):315–324. doi: 10.1111/j.1744-313x.1980.tb00725.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES